The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Cardiovascular outcomes of patients with FL & DLBCL treated with doxorubicin-based chemotherapy
Vincent Camus, MD, University of Rouen, Rouen, France, discusses a retrospective analysis which evaluated the outcomes of patients with follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) receiving standard R-CHOP-like chemotherapy in the frontline setting. Dr Camus comments on the cardiovascular events observed in these patients and further highlights the importance of monitoring patients before, during, and after treatment for cardiovascular toxicities. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
